Related Experiment Video
Updated: Apr 4, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
Lipoprotein(a): Its relevance to the pediatric population
1Division of Cardiology, Department of Internal Medicine, Baylor Scott & White Health, Temple, TX, USA.
Insights
Lipoprotein(a) (Lp(a)) is a key risk factor for cardiovascular disease in children, appearing early in life. Current guidelines don't recommend routine Lp(a) screening due to limited evidence on treatment effectiveness.
Area of Science:
- Cardiovascular Science
- Pediatric Cardiology
- Lipid Metabolism
Background:
- Lipoprotein(a) (Lp(a)) is an inherited, highly atherogenic lipoprotein.
- Unlike other lipoproteins, Lp(a) levels are established early in childhood.
- Lp(a) is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD).
Purpose of the Study:
- To review the significance of Lp(a) in pediatric ASCVD risk.
- To discuss current guidelines regarding Lp(a) screening in youth.
- To highlight the need for lifestyle modifications to mitigate ASCVD risk in children.
Main Methods:
- Literature review of Lp(a) metabolism and clinical significance in pediatrics.
- Analysis of current pediatric cardiovascular health guidelines.
- Discussion of Lp(a) risk factors and management strategies.
Main Results:
- Lp(a) is expressed early in life and is a significant ASCVD risk factor.
- Routine Lp(a) screening is not recommended except for specific high-risk pediatric groups.
- Data on the efficacy of lowering Lp(a) to reduce ASCVD risk is limited.
- Lp(a) elevation significantly increases the risk of arterial ischemic stroke in children.
Conclusions:
- Lp(a) poses a substantial cardiovascular risk in children, necessitating awareness.
- While specific treatments are lacking, managing modifiable risk factors is crucial.
- Education on Lp(a) risks and preventive lifestyle choices is vital for pediatric cardiovascular health.
Abstract:
Lipoprotein(a) (Lp(a)) is a highly atherogenic and heterogeneous lipoprotein that is inherited in an autosomal codominant trait. A unique aspect of this lipoprotein is that it is fully expressed by the first or second year of life in children, a pattern that is distinctly different from other lipoproteins, which typically only reach adult levels after adolescence. Despite decades of research, Lp(a) metabolism is still poorly understood but what is abundantly clear is that it is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD). The Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents does not recommend measuring Lp(a) levels as part of routine screening except in youth with an ischemic or hemorrhagic stroke or youth with a parental history of ASCVD not explained by classical risk factors. One of the reasons that both the pediatric and adult guidelines fail to include this lipoprotein as part of routine lipid screening is the absence of data to show that lowering Lp(a) will reduce current or future ASCVD risk independently of low-density lipoprotein cholesterol (LDL-C) lowering. The cholesterol carried by Lp(a) is included in the low-density lipoprotein cholesterol measurement, but a separate test is used to measure the lipoprotein mass and/or cholesterol carried only by Lp(a). Because levels seem to be largely under genetic control, studies of lifestyle modification have been inconclusive although one study in obese children showed a decrease in the Lp(a) level comparable with the favorable effect on other lipids. The most compelling data regarding the importance of Lp(a) in the pediatric population are the increased risk associated with arterial ischemic stroke, a risk that is comparable with that associated with antiphospholipid antibodies or protein C deficiency. Although no specific pharmaceutical treatments are recommended to lower Lp(a) levels in youth, it is vitally important to educate youth and their parents about the excessive risk associated with this lipoprotein and the need to avoid the acquisition of other lifestyle-related risk factors such as smoking, excess weight, and physical inactivity to preserve more ideal cardiovascular health in adulthood.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Distribution
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Factors Affecting Protein-Drug Binding: Patient-Related Factors
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...

